Scholarlink

<p>We retrospectively analyzed data from the EBMT registry on patients with pretransplant comorbidities associated with cardiovascular risk. Patients who underwent first allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission between 2010 and 2022 from unrelated donors using post-transplant cyclophosphamide (ptCy) or anti-thymocyte globulin (ATG)-based graft-versus-host disease prophylaxis with a history of cardiac disease, arrhythmia, diabetes, obesity or cerebrovascular disease according to the HCT-specific comorbidity index were included. We performed a matched-pair analysis using a propensity score. After matching, 432 patients were included: 313 in the ATG group and 119 in the ptCy group. At 2 years, overall survival was 67.5% (95% CI 61–73.2) and 68.6% (95% CI 56.7–77.8); leukemia-free survival was 60.4% (95% CI 53.8–66.4) and 62.6% (95% CI 50.4–72.6); relapse incidence was 22.1% (95% CI 17–27.7) and 23.2% (95% CI 14.3–33.4); non-relapse mortality was 17.5% (95% CI 13.1–22.4) and 14.1% (95% CI 7.5–22.8), respectively. In conclusion, our study suggests that the use of ptCY for GVHD prophylaxis in patients with preexisting comorbidities associated with cardiovascular risk yields long-term outcomes comparable to those observed with ATG-based approaches.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Posttransplant cyclophosphamide versus antithymocyte globulin in patients with cardiovascular comorbidity undergoing allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in first complete remission from unrelated donors: a retrospective matched-pair analysis from the ALWP of the EBMT

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月3日

查看全文
  • Jan Vydra,
  • Allain-Thibeault Ferhat,
  • Nicolaus Kröger,
  • Tobias Gedde-Dahl,
  • Matthias Eder,
  • Thomas Schroeder,
  • Urpu Salmenniemi,
  • Régis Peffault de Latour,
  • Jakob Passweg,
  • Ibrahim Yakoub-Agha,
  • Alessandro Rambaldi,
  • Robert Zeiser,
  • Matthias Stelljes,
  • Kristina Carlson,
  • Cristina Castilla-Llorente,
  • Alexandros Spyridonidis,
  • Bipin Savani,
  • Fabio Ciceri,
  • Mohamad Mohty

摘要

We retrospectively analyzed data from the EBMT registry on patients with pretransplant comorbidities associated with cardiovascular risk. Patients who underwent first allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission between 2010 and 2022 from unrelated donors using post-transplant cyclophosphamide (ptCy) or anti-thymocyte globulin (ATG)-based graft-versus-host disease prophylaxis with a history of cardiac disease, arrhythmia, diabetes, obesity or cerebrovascular disease according to the HCT-specific comorbidity index were included. We performed a matched-pair analysis using a propensity score. After matching, 432 patients were included: 313 in the ATG group and 119 in the ptCy group. At 2 years, overall survival was 67.5% (95% CI 61–73.2) and 68.6% (95% CI 56.7–77.8); leukemia-free survival was 60.4% (95% CI 53.8–66.4) and 62.6% (95% CI 50.4–72.6); relapse incidence was 22.1% (95% CI 17–27.7) and 23.2% (95% CI 14.3–33.4); non-relapse mortality was 17.5% (95% CI 13.1–22.4) and 14.1% (95% CI 7.5–22.8), respectively. In conclusion, our study suggests that the use of ptCY for GVHD prophylaxis in patients with preexisting comorbidities associated with cardiovascular risk yields long-term outcomes comparable to those observed with ATG-based approaches.